Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Receptor for Advanced Glycation End Products (RAGE) is Expressed Predominantly in Medium Spiny Neurons of tgHD Rat Striatum.

Shi D, Chang JW, Choi J, Connor B, O'Carroll SJ, Nicholson LFB, Kim JH.

Neuroscience. 2018 Jun 1;380:146-151. doi: 10.1016/j.neuroscience.2018.03.042. Epub 2018 Apr 4.

PMID:
29625216
2.

The RAGE receptor and its ligands are highly expressed in astrocytes in a grade-dependant manner in the striatum and subependymal layer in Huntington's disease.

Kim J, Waldvogel HJ, Faull RL, Curtis MA, Nicholson LF.

J Neurochem. 2015 Sep;134(5):927-42. doi: 10.1111/jnc.13178. Epub 2015 Jul 1.

3.

Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease.

Anzilotti S, Giampà C, Laurenti D, Perrone L, Bernardi G, Melone MA, Fusco FR.

Brain Res Bull. 2012 Feb 10;87(2-3):350-8. doi: 10.1016/j.brainresbull.2011.01.009. Epub 2011 Jan 25.

PMID:
21272617
4.
5.

Reduction in subventricular zone-derived olfactory bulb neurogenesis in a rat model of Huntington's disease is accompanied by striatal invasion of neuroblasts.

Kandasamy M, Rosskopf M, Wagner K, Klein B, Couillard-Despres S, Reitsamer HA, Stephan M, Nguyen HP, Riess O, Bogdahn U, Winkler J, von Hörsten S, Aigner L.

PLoS One. 2015 Feb 26;10(2):e0116069. doi: 10.1371/journal.pone.0116069. eCollection 2015.

6.

Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease.

Viana SD, Valero J, Rodrigues-Santos P, Couceiro P, Silva AM, Carvalho F, Ali SF, Fontes-Ribeiro CA, Pereira FC.

J Neurochem. 2016 Aug;138(4):598-609. doi: 10.1111/jnc.13682. Epub 2016 Jun 13.

7.

Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington's disease.

Kirch RD, Meyer PT, Geisler S, Braun F, Gehrig S, Langen KJ, von Hörsten S, Nikkhah G, Cassel JC, Döbrössy MD.

Behav Brain Res. 2013 Feb 15;239:15-26. doi: 10.1016/j.bbr.2012.10.048. Epub 2012 Nov 5.

PMID:
23137697
8.

Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model.

Bode FJ, Stephan M, Wiehager S, Nguyen HP, Björkqvist M, von Hörsten S, Bauer A, Petersén A.

Behav Brain Res. 2009 Dec 14;205(1):175-82. doi: 10.1016/j.bbr.2009.06.031. Epub 2009 Jun 30.

PMID:
19573560
9.

Early expression of the receptor for advanced glycation end products in a toxic model produced by 6-hydroxydopamine in the rat striatum.

Serratos IN, Castellanos P, Pastor N, Millán-Pacheco C, Colín-González AL, Rembao D, Pérez-Montfort R, Cabrera N, Sánchez-García A, Gómez I, Rangel-López E, Santamaria A.

Chem Biol Interact. 2016 Apr 5;249:10-8. doi: 10.1016/j.cbi.2016.02.014. Epub 2016 Feb 18.

PMID:
26902637
10.

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I.

Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16.

11.

Inhibition of the Receptor for Advanced Glycation End-Products (RAGE) Attenuates Neuroinflammation While Sensitizing Cortical Neurons Towards Death in Experimental Subarachnoid Hemorrhage.

Li H, Yu JS, Zhang DD, Yang YQ, Huang LT, Yu Z, Chen RD, Yang HK, Hang CH.

Mol Neurobiol. 2017 Jan;54(1):755-767. doi: 10.1007/s12035-016-9703-y. Epub 2016 Jan 15.

PMID:
26768594
12.

Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease.

Casteels C, Vandeputte C, Rangarajan JR, Dresselaers T, Riess O, Bormans G, Maes F, Himmelreich U, Nguyen H, Van Laere K.

Exp Neurol. 2011 Jun;229(2):440-9. doi: 10.1016/j.expneurol.2011.03.014. Epub 2011 Mar 31.

PMID:
21459091
13.

Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats.

Kántor O, Temel Y, Holzmann C, Raber K, Nguyen HP, Cao C, Türkoglu HO, Rutten BP, Visser-Vandewalle V, Steinbusch HW, Blokland A, Korr H, Riess O, von Hörsten S, Schmitz C.

Neurobiol Dis. 2006 Jun;22(3):538-47. Epub 2006 Feb 9.

PMID:
16480885
14.

Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.

Sepers MD, Smith-Dijak A, LeDue J, Kolodziejczyk K, Mackie K, Raymond LA.

J Neurosci. 2018 Jan 17;38(3):544-554. doi: 10.1523/JNEUROSCI.1739-17.2017. Epub 2017 Nov 30.

15.

AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.

Alto LT, Chen X, Ruhn KA, Treviño I, Tansey MG.

PLoS One. 2014 May 13;9(5):e96544. doi: 10.1371/journal.pone.0096544. eCollection 2014.

16.

S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction.

Tsoporis JN, Izhar S, Leong-Poi H, Desjardins JF, Huttunen HJ, Parker TG.

Circ Res. 2010 Jan 8;106(1):93-101. doi: 10.1161/CIRCRESAHA.109.195834. Epub 2009 Nov 12.

PMID:
19910580
17.

Identification of pyridinoline, a collagen crosslink, as a novel intrinsic ligand for the receptor for advanced glycation end-products (RAGE).

Murakami Y, Fujino T, Kurachi R, Hasegawa T, Usui T, Hayase F, Watanabe H.

Biosci Biotechnol Biochem. 2018 Sep;82(9):1508-1514. doi: 10.1080/09168451.2018.1475213. Epub 2018 May 26.

PMID:
29804507
18.

AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington's disease.

Connor B, Sun Y, von Hieber D, Tang SK, Jones KS, Maucksch C.

Gene Ther. 2016 Mar;23(3):283-95. doi: 10.1038/gt.2015.113. Epub 2015 Dec 24.

PMID:
26704721
19.

Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment.

Gasparotto J, Girardi CS, Somensi N, Ribeiro CT, Moreira JCF, Michels M, Sonai B, Rocha M, Steckert AV, Barichello T, Quevedo J, Dal-Pizzol F, Gelain DP.

J Biol Chem. 2018 Jan 5;293(1):226-244. doi: 10.1074/jbc.M117.786756. Epub 2017 Nov 10.

20.

Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.

Park KH, Lu G, Fan J, Raymond LA, Leavitt BR.

J Huntingtons Dis. 2012;1(1):89-96. doi: 10.3233/JHD-2012-129000.

Supplemental Content

Support Center